Maitake and Reishi are both evidence-backed medicinal mushrooms, but they target different systems. Reishi increased NK cell cytotoxicity by 83.1% in a 2023 double-blind RCT (Chen et al., Foods), while Maitake's D-fraction showed statistically significant immune modulation across 146 measured parameters in a Phase I/II clinical trial. The right choice depends on your goal.
What Makes These Two Mushrooms Different — Bioactives at a Glance
Maitake (Grifola frondosa) and Reishi (Ganoderma lucidum) both contain beta-1,3/1,6-glucans, but their secondary compounds diverge sharply. Reishi carries over 380 identified triterpenoids — including ganoderic acids A, B, and H — that act on the HPA axis and GABA-A receptors. Maitake's signature compound, D-fraction, is a proteo-glucan that binds Dectin-1 receptors on macrophages to directly trigger innate immune responses. This structural difference explains why the two mushrooms produce different clinical effects even when their beta-glucan content looks similar on a supplement label.
Extraction method matters here. Hot-water extraction pulls polysaccharides well from both mushrooms. Reishi additionally benefits from alcohol extraction to capture its lipophilic triterpenes — a dual extraction process that most quality supplements now use. Maitake's D-fraction is water-soluble and heat-stable, so standard hot-water extracts preserve it reliably. If you're reading a Maitake label that lists only "fruiting body powder" without a standardised beta-glucan percentage, you likely won't get consistent D-fraction levels.
Immune Benefits: What the Clinical Data Actually Shows
In a double-blind RCT of 135 adults, 200 mg/day of Reishi beta-glucan for 84 days raised NK cell cytotoxicity by 83.1% (±30%) versus a 4.5% decline in the placebo group (p=0.0001); CD3+ T-cells reached 1,598.8 versus 1,299.4 cells/µL (p=0.001). These are large effect sizes for a food-supplement trial (Chen et al., Foods 2023, PMC9914031).
Maitake's immune data comes from a different angle. A Phase I/II dose-escalation trial in 34 postmenopausal breast cancer patients found statistically significant immune modulation across 25 of 146 measured parameters (overall permutation test p<0.0005), including granulocyte responses and IL-10, IL-2, and TNF-α production exceeding 50% above baseline at 5–7 mg/kg/day D-fraction (Deng et al., PMC3751581). That's a more complex immune picture than simple NK activation — Maitake nudges multiple arms of the immune response simultaneously.
One important nuance: Maitake's D-fraction shows a non-monotonic dose-response. At intermediate doses (roughly 1.5–3 mg/kg), some immune parameters measured in that trial trended downward before rising again at higher doses. This means more isn't always better, and the "dose-response is linear" assumption common in supplement marketing doesn't apply cleanly here.
Reishi as an Adaptogen: HPA Axis, Cortisol, and Sleep
In a 12-week RCT of 50 adults, a Reishi-containing mushroom blend reduced serum cortisol by 5.5% while the placebo group rose 0.8% (p<0.001); ACTH dropped 8.1% (p<0.001); and the HAM-A anxiety score improved 33.5% from baseline. Sleep quality (PSQI) improved 11.1% versus 1.0% in placebo (Hisamuddin et al., Brain and Behavior 2026, PMC12808922).
The mechanism isn't mysterious. Reishi's ganoderic acid triterpenes inhibit 5-alpha reductase and modulate GABA-A receptor activity — the same receptor targeted by benzodiazepines, though through a much gentler partial-agonist pathway. Simultaneously, Reishi polysaccharides dampen NF-kB and COX-2 signalling, reducing the chronic low-grade inflammation that sustains HPA axis overdrive in stressed adults. This dual action — direct GABA modulation plus anti-inflammatory cortisol-lowering — is what separates Reishi from simpler adaptogens like ashwagandha, which primarily targets cortisol via HPA feedback without the direct GABAergic component.
Maitake's Metabolic Edge: Blood Sugar and the GCK Pathway
A 2025 study published in Nutrients found that Maitake polysaccharide GF5000 upregulated glucokinase (GCK) protein expression 2.86-fold and GCK mRNA 2.18-fold versus diabetic control rats; gene expression profiling via cMAP analysis showed a signature matching both metformin and pioglitazone — two frontline diabetes medications (PMC11944433). This is a meaningful mechanistic finding, though human clinical replication is still pending.
Reishi doesn't have comparable metabolic data. Its triterpenoids show some hepatoprotective and lipid-modulating effects in animal studies, but the HPA-axis and immune data dominate its human clinical profile. If metabolic support — blood sugar management, insulin sensitivity, weight-adjacent goals — is a priority, Maitake has the stronger evidence base for that specific target.
For people already on insulin or oral hypoglycaemics like metformin, this creates a drug-interaction concern. Maitake's additive glucose-lowering effect could push blood sugar lower than expected, particularly at doses above 1 g/day standardised extract. This is a conversation to have with your prescriber before stacking.
When to Combine — Synergy, Stacking Logic, and Practical Protocols
A 2019 PLOS ONE study by Vetvicka and Vetvickova found that a Reishi, Shiitake, and Maitake combination formula produced synergistic TNF-α expression in human macrophages — greater than the additive prediction from individual extracts (p<0.05); the combined formula achieved a beta-glucan-to-total-glucan ratio of 0.87, suggesting a high-quality complementary extraction (PMC6837746).
The stacking logic follows from mechanism. Maitake activates the innate immune system via Dectin-1 and stimulates granulopoiesis — processes that are energetically demanding and most relevant during active challenges (illness, post-exercise recovery, high-demand periods). Take it in the morning with food. Reishi's cortisol-lowering and GABAergic effects are better suited to the afternoon or evening, when you want the HPA axis to wind down rather than ramp up. A morning Maitake / evening Reishi split avoids any theoretical overlap between Maitake's stimulating immune activity and Reishi's sedative-adjacent triterpene effects.
Practical daily protocol based on clinical dose ranges: Maitake standardised extract at 1–3 mg/kg body weight (approximately 100–300 mg for a 70 kg adult) in the morning; Reishi powder 1.5–3 g/day or dual-extract 150–300 mg/day in the evening. The Forest Power Blend already combines all three synergistic mushrooms from the PLOS ONE study in a single capsule if you prefer one daily dose.
Safety, Drug Interactions, and Who Should Avoid Each
A 2025 review of Reishi pharmacology confirmed safe dosage at 1.5–6 g/day powdered form or 150–300 mg/day extract, with maximum tolerated dose in animal models exceeding 20 g/kg body weight and no adverse hematological or biochemical changes in a 16-week 3 g/day T2D RCT (PMC12108272). Rare hepatotoxic cases in the literature cluster around very high doses or concurrent alcohol use — not therapeutic doses.
The key safety signals to know:
- Reishi + anticoagulants: Reishi inhibits platelet aggregation. Use with warfarin or aspirin requires medical supervision and INR monitoring.
- Reishi spores at high doses: A 2023 systematic review flagged one case series (5 gastric cancer patients) in which high-dose spore extract elevated CA72-4 tumour marker. No organ damage occurred, but high-dose spore products warrant caution in oncology contexts (PMC10545004).
- Maitake + insulin/oral hypoglycaemics: Additive glucose-lowering — monitor blood sugar closely if combining.
- Maitake non-monotonic dosing: Intermediate doses (1.5–3 mg/kg) showed bidirectional immune effects in the Phase I/II trial. Don't assume higher doses are proportionally better.
- Pregnancy and lactation: Insufficient human safety data for both mushrooms. Avoid unless supervised by a healthcare provider.
Citation capsule — Reishi immune RCT: In the Chen et al. 2023 double-blind RCT (n=135), 200 mg/day of Reishi-derived beta-1,3/1,6-D-glucan for 84 days increased NK cell cytotoxicity by 83.1% (p=0.0001), raised total lymphocytes 14.1% (p=0.002), and improved the CD4/CD8 ratio by 12.9% (p=0.0001) — among the largest immune effect sizes recorded for a single mushroom supplement in a controlled human trial.
Citation capsule — Maitake metabolic mechanism: Maitake polysaccharide GF5000 upregulated glucokinase protein 2.86-fold versus diabetic controls in a 2025 Nutrients study, with a gene-expression fingerprint matching metformin and pioglitazone on connectivity map analysis — suggesting a mechanism similar to frontline diabetes drugs, though human clinical trials have not yet replicated this finding.
Citation capsule — Combination synergy: When Reishi, Shiitake, and Maitake extracts were combined in a single formula, TNF-α expression in human macrophages exceeded the additive prediction of all three individual extracts (p<0.05), confirming pharmacological synergy rather than simple additivity (Vetvicka & Vetvickova, PLOS ONE 2019).
Frequently Asked Questions
Which is better for immune support: Maitake or Reishi?
Both are clinically supported, but through different pathways. Reishi's beta-glucans raised NK cell cytotoxicity by 83.1% in a 2023 RCT of 135 adults. Maitake's D-fraction modulates broader immune parameters including granulocytes and multiple cytokines. For NK-cell–focused immunity, Reishi has stronger human RCT data; for multi-arm immune activation, Maitake's Phase I/II results are compelling.
Can I take Maitake and Reishi together?
Yes — and the combination shows synergy. A 2019 PLOS ONE study found the three-mushroom formula (including both) produced TNF-α responses in macrophages greater than the additive effect of each alone (p<0.05). A common protocol is morning Maitake for metabolic and innate immune support and evening Reishi for cortisol reduction and sleep quality improvement.
Does Reishi really help with stress and sleep?
Human RCT data supports it. In a 12-week trial (n=50), a Reishi-containing blend reduced serum cortisol 5.5% versus a 0.8% rise in placebo (p<0.001), dropped the HAM-A anxiety score by 33.5%, and improved sleep quality (PSQI) by 11.1% (Hisamuddin et al., Brain and Behavior 2026). The mechanism involves triterpene modulation of GABA-A receptors and HPA axis dampening.
Is Maitake good for blood sugar?
Preclinical evidence is strong. A 2025 Nutrients study found Maitake polysaccharide GF5000 upregulated glucokinase 2.86-fold — a key enzyme in glucose metabolism — with a gene-expression signature matching metformin. Human clinical trials are limited. If you're on diabetes medication, discuss with your doctor before adding Maitake due to potential additive glucose-lowering effects.
Is Reishi safe long-term?
At standard doses (1.5–6 g/day powder or 150–300 mg/day extract), a 2025 pharmacology review confirmed no adverse hematological or biochemical changes in a 16-week human trial. Rare hepatotoxicity cases involve very high doses or concurrent alcohol use. People on blood thinners need INR monitoring, and high-dose spore extracts warrant caution in oncology patients based on a 2023 systematic review.
Both Maitake and Reishi earn their place in an evidence-based supplement routine — they're not interchangeable, and that's the point. If your goal is immune activation with a metabolic bonus, start with Maitake or review the Maitake dosage guide to find the right dose range. If stress, cortisol, and sleep are the priority, Reishi is the more direct choice — available as a standardised dual-extract in the Reishi Fruits product. For the full synergistic protocol, the Forest Power Blend combines both alongside Shiitake for the three-mushroom immune synergy confirmed in the PLOS ONE trial. Read the Shiitake vs Maitake comparison if you want to round out your understanding of how the trio works together.